Atalanta Sosnoff Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Atalanta Sosnoff Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-75,000	Closed	-$925K	–	107
2020 Q2	$925K	Buy	+75,000	New	+$848K	0.03%	77
2015 Q4	–	Sell	-793,515	Closed	-$44.8M	–	102
2015 Q3	$44.8M	Buy	793,515 +252,733	+47%	+$16.4M	1.43%	33
2015 Q2	$32M	Sell	540,782 -68,721	-11%	-$4.24M	0.88%	48
2015 Q1	$38M	Sell	609,503 -43,423	-7%	-$2.52M	1.01%	48
2014 Q4	$37.5M	Buy	+652,926	New	+$36.4M	0.93%	51

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Atalanta Sosnoff Capital's TEVA Position: Q3 2020 in Review

Atalanta Sosnoff Capital sold out of Teva Pharmaceuticals (TEVA) in Q3 2020, closing a stake of 75,000 shares — an estimated $925K sold.

Atalanta Sosnoff Capital first reported a position in TEVA in Q4 2014 and held it in 5 quarters. The position peaked at $44.8M in Q3 2015. 443 funds tracked by Wall St. Rank hold TEVA as of Q3 2020.

Atalanta Sosnoff Capital reported no remaining Teva Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Atalanta Sosnoff Capital sold 75,000 Teva Pharmaceuticals shares in Q3 2020, an estimated $925K.
Atalanta Sosnoff Capital first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 5 quarters.
Atalanta Sosnoff Capital's Teva Pharmaceuticals position peaked at $44.8M in Q3 2015.
443 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2020.

Based on Atalanta Sosnoff Capital's 13F filing for Q3 2020, filed 14 Oct 2020.